Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jonsson Comprehensive Cancer Center

Division of University of California
www.cancer.mednet.ucla.edu

Latest From Jonsson Comprehensive Cancer Center

A New Genetic Connection In Liver Cancer -- As Powerful As Her2/neu In Breast?

New data point to a targeted strategy for treating a significant subset of liver cancers and importantly, provide a biomarker for identifying patients who could benefit from the therapy. It's based on the discovery of a correlation between amplification of a growth factor gene and overexpression of the gene's protein product -- a phenomenon that mirrors the way in which amplified Her2/neu gene expression promotes a subset of breast cancer, which led to the development of Herceptin.
BioPharmaceutical Platform Technologies

Clinical Edge

Brief summaries of recent advances in device research and clinical trials, including stem cells that promote bone healing, targeting cancer with nanotechnology, adding radiation to surgery to improve cancer outcomes, finding agressive protate cancer, and a new PET probe that monitors the immune system.
Medical Device

Long-Term Risks of Shutting Down VEGF from Inside the Cell

New research shows that production of VEGF -- a master regulator of blood vessel growth -- from within a cell is an important survival mechanism used by that cell, and that shutting it down could pose long-term risks. The work raises a red flag about long-term use of VEGF-inhibiting small-molecule cancer drugs that travel inside a cell to prevent VEGF expression. It also reinforces the importance of advancing methods for direct delivery of these drugs to tumors.
BioPharmaceutical Regulation

Deal Statistics Quarterly, Q4 2005

In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
BioPharmaceutical Medical Device
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register